Celyad Oncology logo

CYAD - Celyad Oncology Share Price

€6.23 -0.1  -1.6%

Last Trade - 12:12pm

Small Cap
Market Cap £77.4m
Enterprise Value £57.6m
Revenue £9.47k
Position in Universe 546th / 847
Unlock CYAD Revenue
Relative Strength (%)
1m -6.25%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -47.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.15 0.003 8.52 3.54 3.12 0.006 2.25 -47.2%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CelyadOncology revenues increased from EUR0K to EUR5K. Net lossincreased 4% to EUR16.6M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflects Otherexpenses increase from EUR49K to EUR2.7M (expense), OtherESGA increase of 43% to EUR2M (expense), Employee Expensesin R&D increase of 8% to EUR4.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CYAD Revenue Unlock CYAD Revenue

Net Income

CYAD Net Income Unlock CYAD Revenue

Normalised EPS

CYAD Normalised EPS Unlock CYAD Revenue

PE Ratio Range

CYAD PE Ratio Range Unlock CYAD Revenue

Dividend Yield Range

CYAD Dividend Yield Range Unlock CYAD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYAD EPS Forecasts Unlock CYAD Revenue
Profile Summary

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 24, 2007
Public Since July 5, 2013
No. of Shareholders: n/a
No. of Employees: 107
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Euronext - Brussels
Shares in Issue 14,205,156
Free Float (0.0%)
Eligible for
CYAD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CYAD
Upcoming Events for CYAD
Frequently Asked Questions for Celyad Oncology
What is the Celyad Oncology share price?

As of 12:12pm, shares in Celyad Oncology are trading at €6.23, giving the company a market capitalisation of £77.4m. This share price information is delayed by 15 minutes.

How has the Celyad Oncology share price performed this year?

Shares in Celyad Oncology are currently trading at €6.23 and the price has moved by -23.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celyad Oncology price has moved by -30.81% over the past year.

What are the analyst and broker recommendations for Celyad Oncology?

Of the analysts with advisory recommendations for Celyad Oncology, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celyad Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Celyad Oncology next release its financial results?

Celyad Oncology is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Celyad Oncology dividend yield?

Celyad Oncology does not currently pay a dividend.

Does Celyad Oncology pay a dividend?

Celyad Oncology does not currently pay a dividend.

When does Celyad Oncology next pay dividends?

Celyad Oncology does not currently pay a dividend.

How do I buy Celyad Oncology shares?

To buy shares in Celyad Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Celyad Oncology?

Shares in Celyad Oncology are currently trading at €6.23, giving the company a market capitalisation of £77.4m.

Where are Celyad Oncology shares listed? Where are Celyad Oncology shares listed?

Here are the trading details for Celyad Oncology:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: CYAD
What kind of share is Celyad Oncology?

Based on an overall assessment of its quality, value and momentum, Celyad Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Celyad Oncology share price forecast 2021?

Shares in Celyad Oncology are currently priced at €6.23. At that level they are trading at 0.127% discount to the analyst consensus target price of 0.00.

Analysts covering Celyad Oncology currently have a consensus Earnings Per Share (EPS) forecast of -2.087 for the next financial year.

How can I tell whether the Celyad Oncology share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celyad Oncology. Over the past six months, the relative strength of its shares against the market has been -30.95%. At the current price of €6.23, shares in Celyad Oncology are trading at -20.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Celyad Oncology PE Ratio?

We were not able to find PE ratio data for Celyad Oncology.

Who are the key directors of Celyad Oncology?

Celyad Oncology's management team is headed by:

Michel Lussier - CHM
William Wijns - NED
Serge Goblet - NED
Peter De Waele - VRD
Seron Aymeric - OTH
Gaetane Metz - COO
Hanspeter Spek - NED
Georges Rawadi - VBD
Richard Mountfield - VPR
Philippe Dechamps - OTH
Margo Roberts - DRC
Filippo Petti - CEO
Carri Duncan - VPR
Anne Moore - VPR
Marina Udier-Blagovic - DRC
Who are the major shareholders of Celyad Oncology?

Here are the top five shareholders of Celyad Oncology based on the size of their shareholding:

Goblet (Serge) & Thoumyre (Isabelle) Individual Investor
Percentage owned: 15.78% (2.24m shares)
Victory Capital Management Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.74% (816k shares)
Government of the Walloon region Government Agency
Percentage owned: 2.86% (406k shares)
Government of Flanders Government Agency
Percentage owned: 2.47% (351k shares)
BNP Paribas Asset Management Belgium S.A. Investment Advisor
Percentage owned: 0.51% (72.7k shares)
Similar to CYAD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.